Tags

Type your tag names separated by a space and hit enter

Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence.
Cancer Res. 2006 May 01; 66(9):4975-82.CR

Abstract

Observational studies suggest that nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of esophageal adenocarcinoma, but it is not known at what stage they may act in the esophageal inflammation-metaplasia-adenocarcinoma sequence. In an all-Ireland case-control study, we investigated the relationship between the use of NSAIDs and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Patients with esophageal adenocarcinoma, long-segment Barrett's esophagus and population controls were recruited from throughout Ireland. Esophagitis patients were recruited from Northern Ireland only. Data were collected on known and potential risk factors for esophageal adenocarcinoma and on the use of NSAIDs, including aspirin, at least 1 year before interview. Associations between use of NSAIDs and the stages of the esophageal inflammation-metaplasia-adenocarcinoma sequence were estimated by multiple logistic regression. In total, 230 reflux esophagitis, 224 Barrett's esophagus, and 227 esophageal adenocarcinoma and 260 population controls were recruited. Use of aspirin and NSAIDs was associated with a reduced risk of Barrett's esophagus [odds ratio [OR; 95% confidence interval (95% CI)], 0.53 (0.31-0.90) and 0.40 (0.19-0.81), respectively] and esophageal adenocarcinoma [OR (95% CI), 0.57 (0.36-0.93) and 0.58 (0.31-1.08), respectively]. Barrett's esophagus and esophageal adenocarcinoma patients were less likely than controls to have used NSAIDs. Selection or recall bias may explain these results and the results of previous observational studies indicating a protective effect of NSAIDs against esophageal adenocarcinoma. If NSAIDs have a true protective effect on the esophageal inflammation-metaplasia-adenocarcinoma sequence, they may act early in the sequence.

Authors+Show Affiliations

Centre for Clinical and Population Sciences, Queen's University, Belfast, Northern Ireland. l.anderson@qub.ac.ukNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16651456

Citation

Anderson, Lesley A., et al. "Nonsteroidal Anti-inflammatory Drugs and the Esophageal Inflammation-metaplasia-adenocarcinoma Sequence." Cancer Research, vol. 66, no. 9, 2006, pp. 4975-82.
Anderson LA, Johnston BT, Watson RG, et al. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res. 2006;66(9):4975-82.
Anderson, L. A., Johnston, B. T., Watson, R. G., Murphy, S. J., Ferguson, H. R., Comber, H., McGuigan, J., Reynolds, J. V., & Murray, L. J. (2006). Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Research, 66(9), 4975-82.
Anderson LA, et al. Nonsteroidal Anti-inflammatory Drugs and the Esophageal Inflammation-metaplasia-adenocarcinoma Sequence. Cancer Res. 2006 May 1;66(9):4975-82. PubMed PMID: 16651456.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. AU - Anderson,Lesley A, AU - Johnston,Brian T, AU - Watson,R G Peter, AU - Murphy,Seamus J, AU - Ferguson,Heather R, AU - Comber,Harry, AU - McGuigan,Jim, AU - Reynolds,John V, AU - Murray,Liam J, PY - 2006/5/3/pubmed PY - 2006/7/6/medline PY - 2006/5/3/entrez SP - 4975 EP - 82 JF - Cancer research JO - Cancer Res VL - 66 IS - 9 N2 - Observational studies suggest that nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of esophageal adenocarcinoma, but it is not known at what stage they may act in the esophageal inflammation-metaplasia-adenocarcinoma sequence. In an all-Ireland case-control study, we investigated the relationship between the use of NSAIDs and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Patients with esophageal adenocarcinoma, long-segment Barrett's esophagus and population controls were recruited from throughout Ireland. Esophagitis patients were recruited from Northern Ireland only. Data were collected on known and potential risk factors for esophageal adenocarcinoma and on the use of NSAIDs, including aspirin, at least 1 year before interview. Associations between use of NSAIDs and the stages of the esophageal inflammation-metaplasia-adenocarcinoma sequence were estimated by multiple logistic regression. In total, 230 reflux esophagitis, 224 Barrett's esophagus, and 227 esophageal adenocarcinoma and 260 population controls were recruited. Use of aspirin and NSAIDs was associated with a reduced risk of Barrett's esophagus [odds ratio [OR; 95% confidence interval (95% CI)], 0.53 (0.31-0.90) and 0.40 (0.19-0.81), respectively] and esophageal adenocarcinoma [OR (95% CI), 0.57 (0.36-0.93) and 0.58 (0.31-1.08), respectively]. Barrett's esophagus and esophageal adenocarcinoma patients were less likely than controls to have used NSAIDs. Selection or recall bias may explain these results and the results of previous observational studies indicating a protective effect of NSAIDs against esophageal adenocarcinoma. If NSAIDs have a true protective effect on the esophageal inflammation-metaplasia-adenocarcinoma sequence, they may act early in the sequence. SN - 0008-5472 UR - https://www.unboundmedicine.com/medline/citation/16651456/Nonsteroidal_anti_inflammatory_drugs_and_the_esophageal_inflammation_metaplasia_adenocarcinoma_sequence_ L2 - http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=16651456 DB - PRIME DP - Unbound Medicine ER -